9-氯-1-壬醇 | 51308-99-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 9-氯-1-壬醇
• 英文名称: 9-chloro-1-nonanol
• 英文别名: 9-chlorononan-1-ol
• CAS: 51308-99-7
• 化学式: C₉H₁₉ClO
• 分子量: 178.702
• InChiKey: XZWFEAMFGGBZOX-UHFFFAOYSA-N

物化性质

• 熔点：
  28°C
• 沸点：
  254.55°C (rough estimate)
• 密度：
  0.9723 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  11
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2905590090
• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  9-氯-1-壬醇 在 氯化亚砜 、 氯仿 、 甲苯 作用下， 生成 1-(9-chloro-nonyl)-piperidine
  参考文献：
  名称：

  Mahboob; Dhar, Journal Of Scientific and Industrial Research, 1955, vol. 14 B, p. 1,3

  摘要：

  DOI：
• 作为产物：
  描述：

  壬二酸二乙酯 在 盐酸 、 异戊醇 、 sodium 、 Petroleum ether 作用下， 生成 9-氯-1-壬醇
  参考文献：
  名称：

  Bennett; Mosses, Journal of the Chemical Society, 1931, p. 1699

  摘要：

  DOI：

文献信息

• [EN] AZITHROMYCIN DERIVATIVES CONTAINING A PHOSPHONIUM ION AS ANTIBACTERIAL AGENTS<br/>[FR] DÉRIVÉS D'AZITHROMYCINE CONTENANT UN ION PHOSPHONIUM UTILISÉS EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：NOVINTUM BIOTECHNOLOGY GMBH

  公开号：WO2018193124A1

  公开（公告）日：2018-10-25

  This invention relates to compounds that can be used to treat bacterial infections. The compounds comprise azithromycin derivatives having a phosphonium cation tethered to the azithromycin macrocycle. The invention also relates to methods of using said compounds and to pharmaceutical formulations comprising said compounds. The compounds comprise an ion of formula (I): R 5 is independently selected from H, C(O)-C1 -C6 -alkyl or R 5 has the structure: (ll)

  这项发明涉及可用于治疗细菌感染的化合物。这些化合物包括带有磷正离子与阿奇霉素大环相连的阿奇霉素衍生物。发明还涉及使用所述化合物的方法以及包含所述化合物的药物制剂。这些化合物包括公式(I)的离子：R5独立地选自H、C(O)-C1-C6-烷基或R5具有以下结构：(II)
• [EN] SUBSTITUTED 4-AMINO-1-BENZYLPIPERIDINE COMPOUNDS<br/>[FR] COMPOSES DE 4-AMINO-1-BENZYLPIPERIDINE SUBSTITUES
  申请人：THERAVANCE INC

  公开号：WO2005007645A1

  公开（公告）日：2005-01-27

  This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

  这项发明提供了4-氨基-1-苄基哌啶及其相关化合物和药学上可接受的盐，这些化合物可用作毒蕈碱受体拮抗剂。该发明还提供了含有这些化合物的药物组合物；用于制备这些化合物的有用中间体和过程；以及使用这些化合物治疗由毒蕈碱受体介导的疾病状况的方法，如膀胱过度活跃、肠易激综合征、哮喘和慢性阻塞性肺病。
• Studies on the Pharmaceutical Potentiation of Drugs. II. p-Aminosalicylic Acid Derivatives.
  作者：Kiichiro Kakemi、Takaichi Arita、Shikifumi Kitazawa、Yoshihisa Sagawa

  DOI：10.1248/cpb.15.1828

  日期：——

  Nine series of ω-substituted PAS alkyl esters, namely, ω-chloroalkyl, ω-aminoalkyl, ω-diethylaminoalkyl, ω-phenylethylaminoalkyl, ω-morpholinoalkyl, ω-pyrrolidinylalkyl, ω-piperidinoalkyl p-aminosalicylates and alkylene bis-p-aminosalicylates in which the alkyl length varied from ethyl to decyl were synthesized and their evaluations were made with testing their tuberculostatic activities and with measuring their physicochemical properties such as partition coefficients and degrees of protein binding that might considerably influence biological effects of these substances when administered in animal body. These synthesized derivatives have activities as same extent as the parent compound and are more lipid soluble and some of them are less protein bound than PAS. From these observations, it is considered that some of the defects of the parent compound are improved by these chemical modifications. Relationship between structures and these characteristics are also revealed.

  九系列ω-取代对氨基水杨酸烷基酯，即ω-氯代烷基、ω-氨基烷基、ω-二乙氨基烷基、ω-苯乙氨基烷基、ω-吗啉代烷基、ω-吡咯烷基烷基、ω-哌啶基烷基对氨基水杨酸盐及烷撑双对氨基水杨酸酯，其中烷基长度从乙基至癸基变化，已被合成并进行了评估。评估包括测试它们的抗结核活性以及测定它们的物理化学性质，如分配系数和蛋白质结合程度，这些性质可能在动物体内给药时显著影响这些物质的生物效应。这些合成的衍生物具有与母体化合物相同程度的活性，并且脂溶性更高，其中一些的蛋白质结合程度低于PAS。从这些观察结果来看，可以认为通过这些化学修饰改善了母体化合物的一些缺陷。同时揭示了结构与这些特性之间的关系。
• Substituted pyrrolidine and related compounds
  申请人：——

  公开号：US20040254219A1

  公开（公告）日：2004-12-16

  This invention is directed to compounds of formula I: 1 wherein R 1 -R 5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.

  本发明涉及以下结构的化合物：其中R1-R5和a-e如规范中定义；或其药用盐、溶剂化合物或立体异构体。该发明还涉及含有这些化合物的药物组合物；用于制备这些化合物的有用中间体和过程；以及使用这些化合物治疗由毒蕈碱受体介导的疾病状况的方法。
• [EN] ANTIMICROBIAL AGENT, COATING FORMULATION, COMPOSITE SURFACE COATING AND METHODS OF PREPARING THE SAME<br/>[FR] AGENT ANTIMICROBIEN, FORMULATION DE REVÊTEMENT, REVÊTEMENT DE SURFACE COMPOSITE ET LEURS PROCÉDÉS DE PRÉPARATION
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2021107870A1

  公开（公告）日：2021-06-03

  There is provided an antimicrobial agent comprising at least one polymer comprising an optionally substituted heteroaryl amine salt moiety such as an imidazolium salt or an optionally substituted quaternary ammonium cation moiety. The polymer has terminal hydroxyl groups. A coating formulation comprising at least one sol-gel precursor and said antimicrobial agent, as well as a composite surface coating comprising said antimicrobial agent are also provided. Further provided are methods of preparing the antimicrobial agent, composite surface coating and use of the composite surface coating for antimicrobial applications.

  提供一种抗微生物剂，包括至少一种聚合物，其中该聚合物包含一个可选择取代的杂环胺盐基团，例如咪唑盐或可选择取代的季铵阳离子基团。该聚合物具有末端羟基。还提供一种包含至少一种溶胶-凝胶前体和该抗微生物剂的涂层配方，以及包含该抗微生物剂的复合表面涂层。还提供了制备抗微生物剂、复合表面涂层以及使用该复合表面涂层进行抗微生物应用的方法。